Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (August 2017)
16 slides from Glaukos's investor presentation, Aug 9, 2017
Slide 1: August 2017
August 2017 © 2017 Glaukos Corporation.
Slide 2: Disclaimer
2 © 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe th
Slide 3: Transforming glaucoma therapy with micro-scale injectable therapies
glaucoma therapy and highly successful launch global opportunity1 of current treatments of micro-scale 3 © 2017 Glaukos Corporation. is transforming LARGE MARKETUNMET NEEDDEMONSTRATED EXECUTIONJUST THE BEGINNING Growing $5bnSignificant drawbacks Broad reimbursement Advanced portfolio injectable ther
Slide 4: Aging Population Drives Glaucoma Prevalence
Reducing treatment IOP is the only proven for glaucoma 3 intraocular pressure (IOP) 1 OAG 2016 2021 increase from 83mm in 2016 to 2016 2021 Open-Angle Glaucoma All Glaucoma 4 © 2017 Glaukos Corporation. Aging Population Drives Glaucoma Prevalence US GLAUCOMA POPULATION1 (in millions) 5 4 Typically a
Slide 5: How The Eye's Drainage System Works
© 2017 Glaukos Corporation. 5 How The Eye’s Drainage System Works Elevated IOP occurs when Secondary outflow pathway is aqueous humor outflow through the suprachoroidal space the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction
Slide 6: iStent vs. Conventional Surgery
iStent® vs. Conventional Surgery 5tent Conventional Surgery TRABECUlAR MICRO-BYPASS STENT SYSTEM © 2017 Glaukos Corporation. 6
Slide 7: Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy
7 © 2017 Glaukos Corporation. Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy Precision solutions for complete range of glaucoma disease states &progression iStent® iStent Inject® iStent Supra® iDoseTM Used in combination Injectable 2-stent therapy Designed to access
Slide 8: Compelling Clinical Results: Single iStent + Cataract Surgery Through 3 Years
AT 36 MONTHS… CONSISTENT COHORT THROUGH 3 YEARS (n=39) 24 Preop Month 12 Month 24 Month 36 86% decision to implant based on eyes followed through 36 mean number of 8 Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through
Slide 9: Compelling Clinical Results: US Retrospective Studies of Single iStent + Cataract Surgery
20 16.37 15.17 13.6 16 Preop 1M 6M 12M 18M 24M Group 3: IOP not controlled Group 2: IOP not controlled Group 1: IOP controlled 9 Mean IOP (mm Hg) Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: US Retrospective Studies of Single iStent + Cataract Surgery MEAN IOPMEAN IOP TH
Slide 10: Compelling Clinical Results: International Study of 1, 2 and 3 iStents
Demonstrates potential Medications 14.1 14 with preoperative in standalone groups Mean preop medicated Mean preop IOP after Month 18 mean IOP 10 mm Hg © 2017 Glaukos Corporation. Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Mean IOP at 18 Month
Slide 11: Clinical Research Program Statistics
21 Prospective clinical trials currently underway Articles published in journals 11 © 2017 Glaukos Corporation. Clinical Research Program Statistics 65 peer-reviewed
Slide 12: Q2 2017 Financial & Operational Performance
$45 $41.3 least 40% year-over-year growth +45% growth in international sales $25 Reflects continued strong unit 12 © 2017 Glaukos Corporation. Q2 2017 Financial & Operational Performance: Growth Reflects iStent Adoption Trends TOTAL NET SALES (in millions) 16th consecutive quarter of at $40in net sa
Slide 13: Current & Future Potential MIGS Market Participants
Inject Supra 13 © 2017 Glaukos Corporation. Current & Future Potential MIGS Market Participants ALCON CYPASS 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) IVANTIS HYDRUS 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) AL
Slide 14: Financial Summary
(IN MILLIONS) Strong net sales growth, driven Ability to leverage efficient 70.0% 65.0% development, iStent adoption and 14 © 2017 Glaukos Corporation. Financial Summary NET SALESGROSS MARGIN 85.0% primarily by increases in trained 80.0%doctors and ASPs 75.0% manufacturing and cost structure Continu
Slide 15: Growth Strategies: Establishing MIGS as OAG Standard of Care
15 © 2017 Glaukos Corporation. Growth Strategies: Establishing MIGS as OAG Standard of Care 01020304 Increase US iStent Secure FDA approvals Develop, secure Extend global reach of adoption with seasoned with expanded regulatory approval for MIGS-based platform sales force, broad indications for iSte
Slide 16: © 2017 Glaukos Corporation. 16
© 2017 Glaukos Corporation. 16